-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Praliciguat in Focal Segmental Glomerulosclerosis (FSGS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Praliciguat in Focal Segmental Glomerulosclerosis (FSGS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Praliciguat in Focal Segmental Glomerulosclerosis (FSGS) Drug Details: Praliciguat...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sparsentan in Focal Segmental Glomerulosclerosis (FSGS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sparsentan in Focal Segmental Glomerulosclerosis (FSGS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sparsentan in Focal Segmental Glomerulosclerosis (FSGS) Drug Details: Sparsentan...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BI-764198 in Focal Segmental Glomerulosclerosis (FSGS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BI-764198 in Focal Segmental Glomerulosclerosis (FSGS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BI-764198 in Focal Segmental Glomerulosclerosis (FSGS) Drug Details: BI-764198...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VB-119 in Focal Segmental Glomerulosclerosis (FSGS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VB-119 in Focal Segmental Glomerulosclerosis (FSGS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VB-119 in Focal Segmental Glomerulosclerosis (FSGS) Drug Details: VB-119 is...
-
Product Insights
NewFocal Segmental Glomerulosclerosis (FSGS) – Drugs In Development, 2024
Empower your strategies with our Focal Segmental Glomerulosclerosis (FSGS) – Drugs In Development, 2024 report and make more profitable business decisions. Focal segmental glomerulosclerosis (FSGS) is a rare kidney disease that causes scarring of the glomeruli, the tiny filters that remove waste from the blood. The scarring affects only some parts of some glomeruli, hence the name "focal segmental". FSGS can lead to protein loss in the urine, swelling in the body, high cholesterol, and kidney failure. FSGS can have different...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BHV-7000 in Generalized Seizures
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BHV-7000 in Generalized Seizures report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BHV-7000 in Generalized Seizures Drug Details: BHV-7000 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BHV-7000 in Partial Seizure
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BHV-7000 in Partial Seizure report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BHV-7000 in Partial Seizure Drug Details: BHV-7000 is under development for...
-
Product Insights
NewApolipoprotein L1 – Drugs In Development, 2024
The Apolipoprotein L1 pipeline drugs market research report outlays comprehensive information on the Apolipoprotein L1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Genito Urinary System which include indications of Chronic Kidney Disease (Chronic Renal Failure), and Focal Segmental Glomerulosclerosis (FSGS). It also reviews key players involved in Apolipoprotein L1 targeted therapeutics development with respective active and...
-
Product Insights
NewShort Transient Receptor Potential Channel 5 – Drugs In Development, 2024
The Short Transient Receptor Potential Channel 5 pipeline drugs market research report outlays comprehensive information on the Short Transient Receptor Potential Channel 5 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System, Genito Urinary System, Undisclosed, and Oncology which include indications of Anxiety Disorders, Major Depressive Disorder, Focal Segmental Glomerulosclerosis (FSGS), Unspecified, Breast Cancer, and...
-
Product Insights
NewC-C Chemokine Receptor Type 2 – Drugs In Development, 2024
The C-C Chemokine Receptor Type 2 pipeline drugs market research report outlays comprehensive information on the C-C Chemokine Receptor Type 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Genito Urinary System, Central Nervous System, and Gastrointestinal which include indications of Colorectal Cancer, Hepatocellular Carcinoma, Focal Segmental Glomerulosclerosis (FSGS), Diabetic Nephropathy, Alzheimer's Disease, Neuropathic Pain (Neuralgia),...